CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism
Oncology Research and Treatment · 2025
DOI: 10.1159/000545976 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology Research and Treatment, 2025. Verfasst von Marianne Sinn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Oncology and Tumor Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Rivaroxaban, Venous Thromboembolism, Heparin, Low-Molecular-Weight, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Thromboseprophylaxe, Onkologische Pflege
Abstract (Originalsprache)
Introduction
Cancer-associated venous thromboembolism (CAT) is a frequent and medical relevant problem. Guidelines recommend treatment with low molecular weight heparins (LMWH) or direct oral factor-Xa inhibitors as rivaroxaban for ≥3 months. Patient’s preference and convenience is an important factor to guide treatment decision and to support treatment adherence. No data are available so far about patient-reported outcome in CAT.
Methods
CONKO-011/AIO-SUP-0115/ass. was an open-label, prospective, multicenter German phase III trial for cancer patients with newly diagnosed venous thromboembolism (VTE) randomized to rivaroxaban (Riva) or site-specific LMWH. Primary endpoint was patient-reported treatment satisfaction, measured by the Anti-Clot Treatment Scale (ACTS). The 12-item ACTS Burdens scale (primary endpoint after 4 weeks) and the 3-item ACTS Benefits scale were analyzed at 4, 8 and 12 weeks. Secondary endpoints included recurrent VTE, major/clinically relevant bleeding, safety, compliance, overall mortality at 3 and 6 months, quality of life measured by the Treatment Satisfaction Questionnaire for Medication II (TSQM II) and Spitzer Index.
Results
Between 03/2016 and 06/2019, 247 (123 Riva/124 LMWH) patients were randomized. Mean ACTS Burdens scores after 4 weeks were 52.8 versus 51.2 in favor of rivaroxaban (p = 0.019) with mean score differences ranging from 3.3 (week 8; p = 0.001) to 2.4 (week 12; p = 0.006). The treatment effect of ACTS burden was consistent over treatment time (p < 0.001). More patients on LMWH requested to stop study treatment preterm (19.4% versus 11.1%).
Conclusion
Oral treatment with rivaroxaban led to an improvement in patient-reported treatment satisfaction, particularly in reducing anticoagulation-related burden, resulting in less patient-requested treatment stops.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Oncology and Tumor Immunology, Medical Department, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- II Medical Clinic and Polyclinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Internal Medicine and Center for Integrated Oncology, CIO Köln/Bonn, University Hospital of Cologne, Cologne, Germany.
- Department of Hematology and Oncology, Ludmillenstift Hospital Meppen, Meppen, Germany.
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Düsseldorf, Germany.
- Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Zitieren
APA
Sinn, M., Lohneis, A., Mohamed, O., Roderburg, C., Hellmann, M., Südhoff, T., Christoph, D. C., Krziwanie, A., Heinz, J., Semrau, S., Schlenska-Lange, A., Ettrich, T. J., Trappe, R. U., Striefler, J. K., Pelzer, U., Wernecke, K. D., & Riess, H. (2025). CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism. Oncology Research and Treatment. https://doi.org/10.1159/000545976
Vancouver
Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Südhoff T, et al. CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism. Oncology Research and Treatment. 2025. doi:10.1159/000545976
BibTeX
@article{Sinn2025,
author = {Sinn, Marianne and Lohneis, Anja and Mohamed, Omar and Roderburg, Christoph and Hellmann, Matthias and Südhoff, Thomas and Christoph, Daniel C and Krziwanie, Anett and Heinz, Jürgen and Semrau, Sabine and Schlenska-Lange, Anke and Ettrich, Thomas J and Trappe, Ralf Ulrich and Striefler, Jana Kaethe and Pelzer, Uwe and Wernecke, Klaus-Dieter and Riess, Hanno},
title = {CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism},
journal = {Oncology Research and Treatment},
year = {2025},
doi = {10.1159/000545976}
}
EUVIMED